|
1）Ljunggren HG, Karre K. In search of the ʻmissing selfʼ: MHC molecules and NK cell recognition. Immunol Today. 1990; 11: 237-44
|
|
|
|
2）Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. 2011; 155: 14-29
|
|
|
|
|
|
3）Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295: 2097-100
|
|
|
|
|
|
4）Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007; 110(1): 433-40
|
|
|
|
|
|
5）Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009; 23(3): 492-500
|
|
|
|
|
|
6）Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006; 12: 876-84
|
|
|
|
|
|
7）Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant. 2007; 13: 315-28
|
|
|
|
|
|
8）Yabe T, Matsuo K, Hirayasu K, et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant. 2008; 14: 75-87
|
|
|
|
|
|
9）Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009; 113: 5628-34
|
|
|
|
|
|
10）Tanaka J, Morishima Y, Takahashi Y, et al. Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer J. 2013; 3: e164
|
|
|
|
|
|
11）Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nature Reviews. 2013; 13: 133-44
|
|
|
|
|
|
12）Thananchai H, Gillespie G, Martin MP, et al. Cutting edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol. 2007; 178: 33-7
|
|
|
|
|
|
13）Stern M, Ruggeri L, Capanni M, et al. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood. 2008; 112: 708-10
|
|
|
|
|
|
14）Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012; 367: 805-16
|
|
|
|
|
|
15）Joncker NT, Shifrin N, Delebecque F, et al. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med. 2010; 207: 2065-72
|
|
|
|
|